Services
Market Access
Evidence planning and payer engagement for ophthalmic therapies — aligning clinical development choices with HTA, reimbursement, and formulary expectations in the US, EU, and selected global markets.
Market access failures in ophthalmology often originate in development: endpoints that regulators accept but payers question, subgroup plans that cannot support pricing, or evidence packages assembled too late to influence trial design.
BEEÑA-E works with medical, clinical, and commercial leadership to define evidence plans that connect mechanism and trial outcomes to budget impact, treatment pathways, and comparator landscapes. We engage early — typically by Phase 2 — so pivotal trials generate data HTA bodies and US payers can evaluate without supplemental study delays.
We advise on value narrative development, indirect comparison strategy, and country sequencing for launch access. Where specialized HEOR execution is required, we define scope and quality standards for partner teams and integrate outputs into global access planning.
For retina and rare ophthalmic indications, we pay particular attention to imaging-based outcomes, treatment frequency, and administration burden — factors that shape medical policy and physician adoption alongside price.
Key outcomes
- Evidence generation plans aligned to FDA/EMA and major HTA requirements
- Payer and HTA narrative development with ophthalmic comparator context
- Endpoint and subgroup recommendations to support reimbursement dialogue
- Launch access sequencing and market prioritization frameworks
- HEOR workstream governance and specialist partner oversight
Frequently asked questions
No later than Phase 2, and earlier for first-in-class mechanisms or therapies with administration burden that will shape payer policy. Early alignment preserves optionality in pivotal trial design.
We lead evidence strategy, dossier narrative, and gap analysis; specialist HEOR partners often execute country submissions under our scientific and ophthalmic oversight.
We map parallel payer and HTA pathways, identify harmonizable endpoints, and flag where supplemental analyses or subgroup plans are required to avoid post-approval access delays.
Related services
Next steps
Discuss market access priorities
Confidential consultation with senior advisors on your ophthalmic program.